Intellectual Property In India: Novartis Sees Patent Protections To Be In Patients’ Best Interests (Part 3 of 3)
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis’ Gleevec patent battle in India has caught the attention of at least one U.S. lawmaker. Meanwhile, the outcome could impact Indian pharmas.